Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Valuenews2025-11-21T21:25:40+00:00November 21st, 2025|The New York Times|
RFK Jr. Walks a Tightrope on Trump Deal for Obesity Drugsnews2025-11-14T10:02:07+00:00November 14th, 2025|The New York Times|
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Dealnews2025-11-08T12:38:25+00:00November 8th, 2025|The New York Times|
What Trump’s New Drug Pricing Deal Means for People With Obesitynews2025-11-06T21:53:59+00:00November 6th, 2025|The New York Times|
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertisernews2025-09-12T22:09:11+00:00September 12th, 2025|The New York Times|
Trump Moves to Crack Down on Drug Advertisingnews2025-09-10T01:35:07+00:00September 10th, 2025|The New York Times|
Pill Causes Major Weight Loss in Eli Lilly Trial’s Resultsnews2025-08-07T11:37:14+00:00August 7th, 2025|The New York Times|
Trump Demands That Drugmakers Lower Some of Their U.S. Prices by Septembernews2025-07-31T22:24:06+00:00July 31st, 2025|The New York Times|
Trump’s ‘Beautiful Bill’ Actually Pushes Manufacturing Abroadnews2025-06-20T13:56:35+00:00June 20th, 2025|The New York Times|
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drugnews2025-05-12T00:08:25+00:00May 12th, 2025|The New York Times|
